Medy-Tox Inc. (KOSDAQ:086900)
South Korea · Delayed Price · Currency is KRW 85,000
+1,800 (2.16%)
Jun 12, 2026, 3:30 PM KST
Medy-Tox Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 244,021 | 247,290 | 228,622 | 221,121 | 195,096 | 184,870 |
Other Revenue | - | - | - | - | -0 | -0 |
| 244,021 | 247,290 | 228,622 | 221,121 | 195,096 | 184,870 | |
Revenue Growth (YoY) | 2.53% | 8.17% | 3.39% | 13.34% | 5.53% | 31.27% |
Cost of Revenue | 97,483 | 104,449 | 90,038 | 87,625 | 69,048 | 79,397 |
Gross Profit | 146,538 | 142,841 | 138,584 | 133,496 | 126,048 | 105,473 |
Selling, General & Admin | 90,524 | 88,723 | 78,370 | 86,605 | 47,679 | 41,938 |
Research & Development | 29,190 | 29,190 | 29,821 | 25,133 | 23,324 | 23,267 |
Amortization of Goodwill & Intangibles | 2,340 | 2,340 | 2,282 | 1,284 | 799.22 | 834.58 |
Other Operating Expenses | 1,413 | 1,413 | 1,346 | 1,322 | 1,242 | 1,216 |
Operating Expenses | 127,964 | 126,163 | 118,236 | 116,173 | 79,383 | 72,335 |
Operating Income | 18,574 | 16,679 | 20,349 | 17,322 | 46,665 | 33,138 |
Interest Expense | -649.39 | -649.39 | -1,727 | -2,333 | -2,314 | -4,781 |
Interest & Investment Income | 1,395 | 1,395 | 925.15 | 896.43 | 610.76 | 957.22 |
Earnings From Equity Investments | -5,832 | -7,314 | 5,877 | 1,363 | 5,129 | -1,456 |
Currency Exchange Gain (Loss) | -325.57 | -325.57 | 4,387 | 475.22 | 3,425 | 2,111 |
Other Non Operating Income (Expenses) | 1,881 | 106.18 | -4,138 | -605.87 | -715.84 | 108,431 |
EBT Excluding Unusual Items | 15,043 | 9,891 | 25,673 | 17,118 | 52,800 | 138,400 |
Gain (Loss) on Sale of Investments | -4,378 | -4,378 | 126.49 | -593.36 | -3,044 | 2,666 |
Gain (Loss) on Sale of Assets | 305.61 | 305.61 | 323.58 | -671.97 | -230.42 | 131.48 |
Asset Writedown | 764.94 | 764.94 | -8,624 | - | - | -12,932 |
Pretax Income | 11,736 | 6,583 | 17,499 | 15,853 | 49,526 | 128,265 |
Income Tax Expense | -8,459 | -9,076 | 1,425 | 6,163 | 12,930 | 35,003 |
Earnings From Continuing Operations | 20,195 | 15,659 | 16,074 | 9,690 | 36,596 | 93,263 |
Minority Interest in Earnings | 390.5 | 935.18 | 881.22 | 65.28 | 414.16 | 891.27 |
Net Income | 20,585 | 16,594 | 16,955 | 9,755 | 37,010 | 94,154 |
Preferred Dividends & Other Adjustments | 975 | 975 | 975 | 975 | 975.33 | 974.73 |
Net Income to Common | 19,610 | 15,619 | 15,980 | 8,780 | 36,035 | 93,179 |
Net Income Growth | -7.40% | -2.13% | 73.81% | -73.64% | -60.69% | - |
Shares Outstanding (Basic) | 6 | 7 | 7 | 7 | 7 | 6 |
Shares Outstanding (Diluted) | 6 | 7 | 7 | 7 | 7 | 6 |
Shares Change (YoY) | -13.18% | -2.03% | 0.40% | 2.02% | 2.28% | 0.04% |
EPS (Basic) | 3271.97 | 2371.01 | 2376.57 | 1311.06 | 5491.68 | 14587.59 |
EPS (Diluted) | 3271.97 | 2371.01 | 2376.57 | 1311.00 | 5489.34 | 14517.37 |
EPS Growth | 6.27% | -0.23% | 81.28% | -76.12% | -62.19% | - |
Free Cash Flow | 54,238 | 45,749 | 27,830 | 5,862 | 16,304 | 2,452 |
Free Cash Flow Per Share | 9049.68 | 6944.77 | 4138.95 | 875.31 | 2483.66 | 382.01 |
Gross Margin | 60.05% | 57.76% | 60.62% | 60.37% | 64.61% | 57.05% |
Operating Margin | 7.61% | 6.74% | 8.90% | 7.83% | 23.92% | 17.93% |
Profit Margin | 8.04% | 6.32% | 6.99% | 3.97% | 18.47% | 50.40% |
Free Cash Flow Margin | 22.23% | 18.50% | 12.17% | 2.65% | 8.36% | 1.33% |
EBITDA | 38,668 | 36,745 | 40,307 | 32,698 | 61,766 | 51,394 |
EBITDA Margin | 15.85% | 14.86% | 17.63% | 14.79% | 31.66% | 27.80% |
D&A For EBITDA | 20,094 | 20,067 | 19,959 | 15,376 | 15,101 | 18,256 |
EBIT | 18,574 | 16,679 | 20,349 | 17,322 | 46,665 | 33,138 |
EBIT Margin | 7.61% | 6.74% | 8.90% | 7.83% | 23.92% | 17.93% |
Effective Tax Rate | - | - | 8.15% | 38.88% | 26.11% | 27.29% |
Advertising Expenses | - | 6,494 | 7,146 | 5,976 | 3,351 | 2,031 |